Crohn's disease and ulcerative colitis have emerged as global diseases. They affect over 2
million individuals in the North America, 3.2 million in Europe, and millions more worldwide …

Abstract Background and Aims Management of Crohn's disease and ulcerative colitis has
typically relied upon treatment intensification driven by symptoms alone. However, a 'treat-to …

The gut microbiome plays a central role in inflammatory bowel diseases (IBDs)
pathogenesis and propagation. To determine whether the gut microbiome may predict …

Children and adolescents with Crohn's disease (CD) present often with a more complicated
disease course compared to adult patients. In addition, the potential impact of CD on growth …

Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

Summary Background Conventional management of Crohn's disease features incremental
use of therapies. However, early combined immunosuppression (ECI), with a TNF …

Endoscopy plays an essential role in the diagnosis, management, prognosis, and
surveillance of inflammatory bowel disease (IBD), but surprisingly there are few available …

Background & Aims A combination of infliximab and immunomodulators is the most
efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their …

Summary Background Clinical manifestations of Crohn's disease (CD) do not reliably
correlate with endoscopic activity. While treating to achieve clinical remission (CR) has …

Objective The Epi-IBD cohort is a prospective population-based inception cohort of
unselected patients with inflammatory bowel disease from 29 European centres covering a …